Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5635)
All Articles published online
|
May 28, 2009 (publication date) through Apr 30, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Donadon V, Balbi M, Ghersetti M, Grazioli S, Perciaccante A, Della Valentina G, Gardenal R, Dal Mas M, Casarin P, Zanette G, Miranda C. Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease. World J Gastroenterol 2009; 15(20): 2506-2511 [PMID: 19469001 DOI: 10.3748/wjg.15.2506] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v15/i20/2506.htm |
| Number | Citing Articles |
| 1 |
Takumi Kawaguchi, Eitaro Taniguchi, Minoru Itou, Masahiro Sakata, Shuji Sumie, Michio Sata. Insulin resistance and chronic liver disease. World Journal of Hepatology 2011; 3(5): 99-107 doi: 10.4254/wjh.v3.i5.99
|
| 2 |
Giulio Marchesini, Gabriele Forlani, Roberto J. Groszmann, Yasuko Iwakiri, Tamar H. Taddei. Diabetes and hepatocellular cancer risk: Not only a matter of hyperglycemia. Hepatology 2012; 55(4): 1298 doi: 10.1002/hep.25646
|
| 3 |
Laura Pimpin, Helena Cortez-Pinto, Francesco Negro, Emily Corbould, Jeffrey V. Lazarus, Laura Webber, Nick Sheron. Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify prevention policies. Journal of Hepatology 2018; 69(3): 718 doi: 10.1016/j.jhep.2018.05.011
|
| 4 |
Samy Suissa, Laurent Azoulay. Metformin and the Risk of Cancer. Diabetes Care 2012; 35(12): 2665 doi: 10.2337/dc12-0788
|
| 5 |
Marion Donnier-Maréchal, Sébastien Vidal. Glycogen phosphorylase inhibitors: a patent review (2013 - 2015). Expert Opinion on Therapeutic Patents 2016; 26(2): 199 doi: 10.1517/13543776.2016.1131268
|
| 6 |
Dana J. Herrigel, Rebecca A. Moss. Diabetes Mellitus as a Novel Risk Factor for Gastrointestinal Malignancies. Postgraduate Medicine 2014; 126(6): 106 doi: 10.3810/pgm.2014.10.2825
|
| 7 |
Sara Salehi Hammerstad, Shira Frankel Grock, Hanna J. Lee, Alia Hasham, Nina Sundaram, Yaron Tomer. Diabetes and Hepatitis C: A Two-Way Association. Frontiers in Endocrinology 2015; 6 doi: 10.3389/fendo.2015.00134
|
| 8 |
Hiroshi Noto, Atsushi Goto, Tetsuro Tsujimoto, Mitsuhiko Noda, Giuseppe Biondi-Zoccai. Cancer Risk in Diabetic Patients Treated with Metformin: A Systematic Review and Meta-analysis. PLoS ONE 2012; 7(3): e33411 doi: 10.1371/journal.pone.0033411
|
| 9 |
Vincent Kaddai, Francesco Negro. Current understanding of insulin resistance in hepatitis C. Expert Review of Gastroenterology & Hepatology 2011; 5(4): 503 doi: 10.1586/egh.11.43
|
| 10 |
Qingyun Zhang, Jian Kong, Shuying Dong, Wenlei Xu, Wenbing Sun. Metformin exhibits the anti-proliferation and anti-invasion effects in hepatocellular carcinoma cells after insufficient radiofrequency ablation. Cancer Cell International 2017; 17(1) doi: 10.1186/s12935-017-0418-6
|
| 11 |
Wei‐Hsu Ko, Sherry Yueh‐Hsia Chiu, Kuo‐Ching Yang, Hsiu‐Hsi Chen. Diabetes, hepatitis virus infection and hepatocellular carcinoma: A case–control study in hepatitis endemic area. Hepatology Research 2012; 42(8): 774 doi: 10.1111/j.1872-034X.2012.00979.x
|
| 12 |
Chenwi M. Ambe, Amit Mahipal, Jimmy Fulp, Lu Chen, Mokenge P. Malafa, Jose G. Trevino. Effect of Metformin Use on Survival in Resectable Pancreatic Cancer: A Single-Institution Experience and Review of the Literature. PLOS ONE 2016; 11(3): e0151632 doi: 10.1371/journal.pone.0151632
|
| 13 |
Yonghua Yang. Metformin for cancer prevention. Frontiers of Medicine 2011; 5(2): 115 doi: 10.1007/s11684-011-0112-3
|
| 14 |
Weiling Leng, Juan Jiang, Bing Chen, Qinan Wu. Metformin and Malignant Tumors: Not Over the Hill. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2021; : 3673 doi: 10.2147/DMSO.S326378
|
| 15 |
Cristina Bosetti, Matteo Franchi, Federica Nicotra, Rosario Asciutto, Luca Merlino, Carlo La Vecchia, Giovanni Corrao. Insulin and other antidiabetic drugs and hepatocellular carcinoma risk: a nested case-control study based on Italian healthcare utilization databases. Pharmacoepidemiology and Drug Safety 2015; 24(7): 771 doi: 10.1002/pds.3801
|
| 16 |
Masahiro Sakata, Akihiko Kawahara, Takumi Kawaguchi, Jun Akiba, Tomoki Taira, Eitaro Taniguchi, Mitsuhiko Abe, Hironori Koga, Masayoshi Kage, Michio Sata. Decreased expression of insulin and increased expression of pancreatic transcription factor PDX-1 in islets in patients with liver cirrhosis: a comparative investigation using human autopsy specimens. Journal of Gastroenterology 2013; 48(2): 277 doi: 10.1007/s00535-012-0633-9
|
| 17 |
Wai Gin Lee, Cameron I. Wells, John L. McCall, Rinki Murphy, Lindsay D. Plank. Prevalence of diabetes in liver cirrhosis: A systematic review and meta‐analysis. Diabetes/Metabolism Research and Reviews 2019; 35(6) doi: 10.1002/dmrr.3157
|
| 18 |
Takumi Kawaguchi, Takuji Torimura. Impact of insulin resistance on hepatocellular carcinoma. Kanzo 2015; 56(4): 127 doi: 10.2957/kanzo.56.127
|
| 19 |
Hsin-Hwa Tsai, Hong-Yue Lai, Yueh-Chiu Chen, Chien-Feng Li, Huei-Sheng Huang, Hsiao-Sheng Liu, Yau-Sheng Tsai, Ju-Ming Wang. Metformin promotes apoptosis in hepatocellular carcinoma through the CEBPD-induced autophagy pathway. Oncotarget 2017; 8(8): 13832 doi: 10.18632/oncotarget.14640
|
| 20 |
Andreas E. Buchs, Barbara G. Silverman. Incidence of malignancies in patients with diabetes mellitus and correlation with treatment modalities in a large Israeli health maintenance organization: a historical cohort study. Metabolism 2011; 60(10): 1379 doi: 10.1016/j.metabol.2011.05.002
|
| 21 |
Victoria Svop Jensen, Christian Fledelius, Christina Zachodnik, Jesper Damgaard, Helle Nygaard, Kristina Steinicke Tornqvist, Rikke Kaae Kirk, Birgitte Martine Viuff, Erik Max Wulff, Jens Lykkesfeldt, Henning Hvid. Insulin treatment improves liver histopathology and decreases expression of inflammatory and fibrogenic genes in a hyperglycemic, dyslipidemic hamster model of NAFLD. Journal of Translational Medicine 2021; 19(1) doi: 10.1186/s12967-021-02729-1
|
| 22 |
Minh Truong Do, Hyung Gyun Kim, Tilak Khanal, Jae Ho Choi, Dong Hee Kim, Tae Cheon Jeong, Hye Gwang Jeong. Metformin inhibits heme oxygenase-1 expression in cancer cells through inactivation of Raf-ERK-Nrf2 signaling and AMPK-independent pathways. Toxicology and Applied Pharmacology 2013; 271(2): 229 doi: 10.1016/j.taap.2013.05.010
|
| 23 |
Stephen A Harrison, Matthew J Lincoln, Katharine K Roberts. Insulin resistance in chronic hepatitis C: the search for effective drug treatment continues. Expert Review of Gastroenterology & Hepatology 2012; 6(4): 401 doi: 10.1586/egh.12.29
|
| 24 |
Manal M. Hassan, Steven A. Curley, Donghui Li, Ahmed Kaseb, Marta Davila, Eddie K. Abdalla, Milind Javle, Dalia M. Moghazy, Richard D. Lozano, James L. Abbruzzese, Jean‐Nicolas Vauthey. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer 2010; 116(8): 1938 doi: 10.1002/cncr.24982
|
| 25 |
C. Senthil Kumar, M.D. Raja, D. Sathish Sundar, M. Gover Antoniraj, K. Ruckmani. Hyaluronic acid co-functionalized gold nanoparticle complex for the targeted delivery of metformin in the treatment of liver cancer (HepG2 cells). Carbohydrate Polymers 2015; 128: 63 doi: 10.1016/j.carbpol.2015.04.010
|
| 26 |
Dara Cannata, Yvonne Fierz, Archana Vijayakumar, Derek LeRoith. Type 2 Diabetes and Cancer: What Is the Connection?. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 2010; 77(2): 197 doi: 10.1002/msj.20167
|
| 27 |
Kaizhen Wang, Kuojun Zhang, Xiangyu Zhang, Dong Chen, Sheng Jiang. Recent Insights of Metformin on Hepatocellular Carcinoma (HCC). Mini-Reviews in Medicinal Chemistry 2023; 23(11): 1154 doi: 10.2174/1389557522666220623150717
|
| 28 |
E.K.K. Lam, G.D. Batty, R.R. Huxley, A.L.C. Martiniuk, F. Barzi, T.H. Lam, C.M.M. Lawes, G.G. Giles, T. Welborn, H. Ueshima, A. Tamakoshi, J. Woo, H.C. Kim, X. Fang, S. Czernichow, M. Woodward. Associations of diabetes mellitus with site-specific cancer mortality in the Asia-Pacific region. Annals of Oncology 2011; 22(3): 730 doi: 10.1093/annonc/mdq405
|
| 29 |
S. Bo, A. Benso, M. Durazzo, E. Ghigo. Does use of metformin protect against cancer in Type 2 diabetes mellitus?. Journal of Endocrinological Investigation 2012; 35(2): 231 doi: 10.1007/BF03345423
|
| 30 |
Hui-Wen Tseng, Sung-Chou Li, Kuo-Wang Tsai. Metformin Treatment Suppresses Melanoma Cell Growth and Motility Through Modulation of microRNA Expression. Cancers 2019; 11(2): 209 doi: 10.3390/cancers11020209
|
| 31 |
Valter Donadon, Massimiliano Balbi, Giorgio Zanette. Hyperinsulinemia and risk for hepatocellular carcinoma in patients with chronic liver diseases and Type 2 diabetes mellitus. Expert Review of Gastroenterology & Hepatology 2009; 3(5): 465 doi: 10.1586/egh.09.41
|
| 32 |
LORENA CASTRO S., GUILLERMO SILVA P.. HÍGADO GRASO NO ALCOHÓLICO. Revista Médica Clínica Las Condes 2015; 26(5): 600 doi: 10.1016/j.rmclc.2015.09.006
|
| 33 |
Cristóbal Belda-Iniesta, Olga Pernía, Rafael Simó. Metformin: a new option in cancer treatment. Clinical and Translational Oncology 2011; 13(6): 363 doi: 10.1007/s12094-011-0669-y
|
| 34 |
Ji-Yeon Lee, Suk-Yong Jang, Chung Mo Nam, Eun Seok Kang. Incident Hepatocellular Carcinoma Risk in Patients Treated with a Sulfonylurea: A Nationwide, Nested, Case-Control Study. Scientific Reports 2019; 9(1) doi: 10.1038/s41598-019-44447-1
|
| 35 |
Kavita Bhalla, Bor Jang Hwang, Ruby E. Dewi, William Twaddel, Olga G. Goloubeva, Kwok-Kin Wong, Neeraj K. Saxena, Shyam Biswal, Geoffrey D. Girnun. Metformin Prevents Liver Tumorigenesis by Inhibiting Pathways Driving Hepatic Lipogenesis. Cancer Prevention Research 2012; 5(4): 544 doi: 10.1158/1940-6207.CAPR-11-0228
|
| 36 |
Ehab Abdel-Atti. HCC Burden in Egypt. Gastroenterology & Hepatology : Open Access 2015; 2(3) doi: 10.15406/ghoa.2015.02.00045
|
| 37 |
Shujuan Ma, Yixiang Zheng, Yanni Xiao, Pengcheng Zhou, Hongzhuan Tan. Meta-analysis of studies using metformin as a reducer for liver cancer risk in diabetic patients. Medicine 2017; 96(19): e6888 doi: 10.1097/MD.0000000000006888
|
| 38 |
Chien-Hsieh Chiang, Chia-Sheng Kuo, Wan-Wan Lin, Jun-Han Su, Jin-De Chen, Kuo-Chin Huang. Chronic Viral Hepatitis Signifies the Association of Premixed Insulin Analogues with Liver Cancer Risks: A Nationwide Population-Based Study. International Journal of Environmental Research and Public Health 2019; 16(12): 2097 doi: 10.3390/ijerph16122097
|
| 39 |
M A Pierotti, F Berrino, M Gariboldi, C Melani, A Mogavero, T Negri, P Pasanisi, S Pilotti. Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multi-faceted effects. Oncogene 2013; 32(12): 1475 doi: 10.1038/onc.2012.181
|
| 40 |
Cristina Margini, Jean F. Dufour. The story of HCC in NAFLD: from epidemiology, across pathogenesis, to prevention and treatment. Liver International 2016; 36(3): 317 doi: 10.1111/liv.13031
|
| 41 |
Harold E. Lebovitz. Malignancy Concerns With Antidiabetic Therapies: Examining the Evidence. Endocrine Practice 2010; 16: 14 doi: 10.1016/S1530-891X(20)42872-1
|
| 42 |
J K Dyson, Q M Anstee, S McPherson. Republished: Non-alcoholic fatty liver disease: a practical approach to treatment. Postgraduate Medical Journal 2015; 91(1072): 92 doi: 10.1136/postgradmedj-2013-100404rep
|
| 43 |
Naim Alkhouri, Arthur McCullough. Obesity, Inflammation and Cancer. 2013; : 219 doi: 10.1007/978-1-4614-6819-6_9
|
| 44 |
Panagiota Papanagnou, Theodora Stivarou, Maria Tsironi. Unexploited Antineoplastic Effects of Commercially Available Anti-Diabetic Drugs. Pharmaceuticals 2016; 9(2): 24 doi: 10.3390/ph9020024
|
| 45 |
Masafumi Ono, Koji Fujita, Kiyoyuki Kobayashi, Tsutomu Masaki. Influence of diabetes mellitus and effectiveness of metformin on hepatocellular carcinoma. Hepatology Research 2023; 53(7): 579 doi: 10.1111/hepr.13912
|
| 46 |
Ryan J O Dowling, Saroj Niraula, Vuk Stambolic, Pamela J Goodwin. Metformin in cancer: translational challenges. Journal of Molecular Endocrinology 2012; 48(3): R31 doi: 10.1530/JME-12-0007
|
| 47 |
Vivek Dwivedi, Shahnawaz Sameem, Mahfoozur Rahman, Prateek Pathak, Amita Verma. Hormone Related Cancer Mechanistic and Nanomedicines. 2022; : 111 doi: 10.1007/978-981-19-5558-7_6
|
| 48 |
Sara Gandini, Matteo Puntoni, Brandy M. Heckman-Stoddard, Barbara K. Dunn, Leslie Ford, Andrea DeCensi, Eva Szabo. Metformin and Cancer Risk and Mortality: A Systematic Review and Meta-analysis Taking into Account Biases and Confounders. Cancer Prevention Research 2014; 7(9): 867 doi: 10.1158/1940-6207.CAPR-13-0424
|
| 49 |
Chin‐Hsiao Tseng. Diabetes is not an independent risk factor for hepatocellular carcinoma. Diabetes/Metabolism Research and Reviews 2013; 29(7): 515 doi: 10.1002/dmrr.2422
|
| 50 |
Ilaria Imarisio, Chiara Paglino, Carlo Ganini, Luigi Magnani, Riccardo Caccialanza, Camillo Porta. The effect of sorafenib treatment on the diabetic status of patients with renal cell or hepatocellular carcinoma. Future Oncology 2012; 8(8): 1051 doi: 10.2217/fon.12.74
|
| 51 |
K. H. Williams, N. A. Shackel, M. D. Gorrell, S. V. McLennan, S. M. Twigg. Diabetes and Nonalcoholic Fatty Liver Disease: A Pathogenic Duo. Endocrine Reviews 2013; 34(1): 84 doi: 10.1210/er.2012-1009
|
| 52 |
Navid Sadeghi, James L. Abbruzzese, Sai-Ching J. Yeung, Manal Hassan, Donghui Li. Metformin Use Is Associated with Better Survival of Diabetic Patients with Pancreatic Cancer. Clinical Cancer Research 2012; 18(10): 2905 doi: 10.1158/1078-0432.CCR-11-2994
|
| 53 |
Madhia Shahid, Gabriel Q. Shaibi, Hayley Baines, Pamela Garcia-Filion, Zoe Gonzalez-Garcia, Micah Olson. Risk of hypoglycemia in youth with type 2 diabetes on insulin. Journal of Pediatric Endocrinology and Metabolism 2018; 31(6): 625 doi: 10.1515/jpem-2018-0014
|
| 54 |
Andrea DeCensi, Matteo Puntoni, Pamela Goodwin, Massimiliano Cazzaniga, Alessandra Gennari, Bernardo Bonanni, Sara Gandini. Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis. Cancer Prevention Research 2010; 3(11): 1451 doi: 10.1158/1940-6207.CAPR-10-0157
|
| 55 |
Guang-Ying Shi, Yu Sun, Xing-Chen Liang, Jing-Dong Xie. Clinical significance of expression of serum insulin-like growth factor-1 in patients with primary liver cancer and diabetes mellitus. World Chinese Journal of Digestology 2021; 29(5): 236 doi: 10.11569/wcjd.v29.i5.236
|
| 56 |
Sahil Mittal, Donna L. White, Fasiha Kanwal, Norman Sussman, Hashem B. El-Serag. Nonalcoholic Fatty Liver Disease (NAFLD) and Hepatocellular Carcinoma: How Common?. Current Hepatology Reports 2015; 14(2): 87 doi: 10.1007/s11901-015-0259-5
|
| 57 |
Wen-Yi Shau, Yu-Yun Shao, Yi-Chun Yeh, Zhong-Zhe Lin, Raymond Kuo, Chih-Hung Hsu, Chiun Hsu, Ann-Lii Cheng, Mei-Shu Lai. Diabetes Mellitus Is Associated with Increased Mortality in Patients Receiving Curative Therapy for Hepatocellular Carcinoma. The Oncologist 2012; 17(6): 856 doi: 10.1634/theoncologist.2012-0065
|
| 58 |
Cheng-Chieh Lin, Jen-Huai Chiang, Chia-Ing Li, Chiu-Shong Liu, Wen-Yuan Lin, Teng-Fu Hsieh, Tsai-Chung Li. Cancer risks among patients with type 2 diabetes: a 10-year follow-up study of a nationwide population-based cohort in Taiwan. BMC Cancer 2014; 14(1) doi: 10.1186/1471-2407-14-381
|
| 59 |
Yu-Wei Chen, Han-Hsiang Chen, Tsang-En Wang, Ching-Wei Chang, Chen-Wang Chang, Wei-Che Chen, Chih-Jen Wu. The dissociation between the diabetes and both Child–Pugh score and in-hospital mortality in cirrhotic patients due to hepatitis B, hepatitis C, or alcoholic. Hepatology International 2011; 5(4): 955 doi: 10.1007/s12072-011-9274-y
|
| 60 |
Xu Li, Xiaocong Wang, Pujun Gao. Diabetes Mellitus and Risk of Hepatocellular Carcinoma. BioMed Research International 2017; 2017: 1 doi: 10.1155/2017/5202684
|
| 61 |
Giovan Giuseppe Di Costanzo, Raffaella Tortora, Filomena Morisco, Luigi Addario, Maria Guarino, Gabriella Cordone, Luigia Falco, Nicola Caporaso. Impact of Diabetes on Outcomes of Sorafenib Therapy for Hepatocellular Carcinoma. Targeted Oncology 2017; 12(1): 61 doi: 10.1007/s11523-016-0454-5
|
| 62 |
Mervat M. El-Eshmawy, Tharwat S. Kandil, Hala A. Abd El-Hafez, Ahmed Y. Abo El yazid, El Hadidy M. El Hadidy. Type 2 diabetes mellitus is a risk factor for hepatocellular carcinoma in Egyptian patients with HCV-related cirrhosis. International Journal of Diabetes in Developing Countries 2014; 34(4): 210 doi: 10.1007/s13410-013-0186-3
|
| 63 |
Young Hoon Sul, Myung Sun Lee, Eun Young Cha, Phuong Thien Thuong, Nguyen Minh Khoi, In Sang Song. An <i>ent</i>-Kaurane Diterpenoid from <i>Croton tonkinensis</i> Induces Apoptosis by Regulating AMP-Activated Protein Kinase in SK-HEP1 Human Hepatocellular Carcinoma Cells. Biological and Pharmaceutical Bulletin 2013; 36(1): 158 doi: 10.1248/bpb.b12-00873
|
| 64 |
Aparna Bhat, Giada Sebastiani, Mamatha Bhat. Systematic review: Preventive and therapeutic applications of metformin in liver disease. World Journal of Hepatology 2015; 7(12): 1652-1659 doi: 10.4254/wjh.v7.i12.1652
|
| 65 |
Mona A. Abu El Makarem, Mohammed Eslam, Douaa Sayed, Mohamed Shawkat, Naglaa K. Idriss, Elwy M. Soliman, Tahra Sherif, Ragaa Abdelshaheed, Hesham Abdelhailm, Mohamed A. Sahrawi, Sahar Elheney. Diabetes worsening of hepatitis C cirrhosis: Are alterations in monocytic tissue factor (CD 142) is the cause?. Annals of Hepatology 2014; 13(1): 27 doi: 10.1016/S1665-2681(19)30901-9
|
| 66 |
Ian N. Hines, Hadley J. Hartwell, Yan Feng, Elizabeth J. Theve, Gregory A. Hall, Sara Hashway, Jessica Connolly, Michelle Fecteau, James G. Fox, Arlin B. Rogers. Insulin Resistance and Metabolic Hepatocarcinogenesis with Parent-of-Origin Effects in A×B Mice. The American Journal of Pathology 2011; 179(6): 2855 doi: 10.1016/j.ajpath.2011.08.014
|
| 67 |
Waihong Chung, Kittichai Promrat, Jack Wands. Clinical implications, diagnosis, and management of diabetes in patients with chronic liver diseases. World Journal of Hepatology 2020; 12(9): 533-557 doi: 10.4254/wjh.v12.i9.533
|
| 68 |
Meei-Shyuan Lee, Chih-Cheng Hsu, Mark L Wahlqvist, Hsin-Ni Tsai, Yu-Hung Chang, Yi-Chen Huang. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer 2011; 11(1) doi: 10.1186/1471-2407-11-20
|
| 69 |
Matthew M. Yeh, Yajuan Liu, Michael Torbenson. Steatohepatitic variant of hepatocellular carcinoma in the absence of metabolic syndrome or background steatosis: a clinical, pathological, and genetic study. Human Pathology 2015; 46(11): 1769 doi: 10.1016/j.humpath.2015.07.018
|
| 70 |
Zachary Bloomgarden, Yehuda Handelsman. Cancer mortality and insulin glargine. Journal of Diabetes 2009; 1(3): 131 doi: 10.1111/j.1753-0407.2009.00038.x
|
| 71 |
S. R. Lord, N. Patel, D. Liu, J. Fenwick, F. Gleeson, F. Buffa, A. L. Harris. Neoadjuvant Window Studies of Metformin and Biomarker Development for Drugs Targeting Cancer Metabolism. JNCI Monographs 2015; 2015(51): 81 doi: 10.1093/jncimonographs/lgv011
|
| 72 |
Ryosuke Tateishi, Koji Uchino, Naoto Fujiwara, Tetsuo Takehara, Takeshi Okanoue, Masataka Seike, Hitoshi Yoshiji, Hiroshi Yatsuhashi, Masahito Shimizu, Takuji Torimura, Mitsuhiko Moriyama, Isao Sakaida, Hiroyuki Okada, Tetsuhiro Chiba, Makoto Chuma, Kazuhiko Nakao, Hajime Isomoto, Yutaka Sasaki, Shuichi Kaneko, Tsutomu Masaki, Kazuaki Chayama, Kazuhiko Koike. A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011–2015 update. Journal of Gastroenterology 2019; 54(4): 367 doi: 10.1007/s00535-018-1532-5
|
| 73 |
Kira Harris, Lisa Smith. Safety and Efficacy of Metformin in Patients With Type 2 Diabetes Mellitus and Chronic Hepatitis C. Annals of Pharmacotherapy 2013; 47(10): 1348 doi: 10.1177/1060028013503108
|
| 74 |
Stephanie Klein, Jean-François Dufour. Nonalcoholic fatty liver disease and hepatocellular carcinoma. Hepatic Oncology 2017; 4(3): 83 doi: 10.2217/hep-2017-0013
|
| 75 |
Simona Bo, Anna Castiglione, Ezio Ghigo, Luigi Gentile, Marilena Durazzo, Paolo Cavallo-Perin, Giovannino Ciccone. Mortality outcomes of different sulphonylurea drugs: the results of a 14-year cohort study of type 2 diabetic patients. European Journal of Endocrinology 2013; 169(1): 117 doi: 10.1530/EJE-13-0299
|
| 76 |
Matthias Evert, Diego F. Calvisi, Katja Evert, Valentina De Murtas, Gioia Gasparetti, Sandra Mattu, Giulia Destefanis, Sara Ladu, Antje Zimmermann, Salvatore Delogu, Sara Thiel, Andrea Thiele, Silvia Ribback, Frank Dombrowski. V-AKT murine thymoma viral oncogene homolog/mammalian target of rapamycin activation induces a module of metabolic changes contributing to growth in insulin-induced hepatocarcinogenesis. Hepatology 2012; 55(5): 1473 doi: 10.1002/hep.25600
|
| 77 |
Eshani J. Choksi, Mohammad Elsayed, Nima Kokabi. Antitumor Activity of Metformin Combined with Locoregional Therapy for Liver Cancer: Evidence and Future Directions. Cancers 2023; 15(18): 4538 doi: 10.3390/cancers15184538
|
| 78 |
Emmanuel Beck, André J. Scheen. Quels bénéfices antitumoraux attendre de la metformine ?. Annales d'Endocrinologie 2013; 74(2): 137 doi: 10.1016/j.ando.2013.02.009
|
| 79 |
Chien-Ming Lin, Hui-Ling Huang, Fang-Ying Chu, Hueng-Chuen Fan, Hung-An Chen, Der-Ming Chu, Li-Wei Wu, Chung-Ching Wang, Wei-Liang Chen, Shih-Hua Lin, Shinn-Ying Ho, Suminori Akiba. Association between Gastroenterological Malignancy and Diabetes Mellitus and Anti-Diabetic Therapy: A Nationwide, Population-Based Cohort Study. PLOS ONE 2015; 10(5): e0125421 doi: 10.1371/journal.pone.0125421
|
| 80 |
Donghui LI. Metformin as an antitumor agent in cancer prevention and treatment. Journal of Diabetes 2011; 3(4): 320 doi: 10.1111/j.1753-0407.2011.00119.x
|
| 81 |
Javier Ampuero, Manuel Romero-Gomez. Prevention of hepatocellular carcinoma by correction of metabolic abnormalities: Role of statins and metformin. World Journal of Hepatology 2015; 7(8): 1105-1111 doi: 10.4254/wjh.v7.i8.1105
|
| 82 |
Siddharth Singh, Preet Paul Singh, Abha Goyal Singh, Mohammad Hassan Murad, William Sanchez. Anti-Diabetic Medications and the Risk of Hepatocellular Cancer: A Systematic Review and Meta-Analysis. American Journal of Gastroenterology 2013; 108(6): 881 doi: 10.1038/ajg.2013.5
|
| 83 |
Yao-Yao Zhou, Gui-Qi Zhu, Tian Liu, Ji-Na Zheng, Zhang Cheng, Tian-Tian Zou, Martin Braddock, Shen-Wen Fu, Ming-Hua Zheng. Systematic Review with Network Meta-Analysis: Antidiabetic Medication and Risk of Hepatocellular Carcinoma. Scientific Reports 2016; 6(1) doi: 10.1038/srep33743
|
| 84 |
Angela Mazza, Barbara Fruci, Giorgia Anna Garinis, Stefania Giuliano, Roberta Malaguarnera, Antonino Belfiore. The Role of Metformin in the Management of NAFLD. Experimental Diabetes Research 2012; 2012: 1 doi: 10.1155/2012/716404
|
| 85 |
Takumi Kawaguchi, Dan Nakano, Takuji Torimura. Alcoholic/Non-Alcoholic Digestive Diseases. 2019; : 65 doi: 10.1007/978-981-13-1465-0_7
|
| 86 |
Harold E. Lebovitz. Insulin: Potential Negative Consequences of Early Routine Use in Patients With Type 2 Diabetes. Diabetes Care 2011; 34(Supplement_2): S225 doi: 10.2337/dc11-s225
|
| 87 |
Claudia A. Couto, Claudio L. Gelape, Fernando Calmet, Paul Martin, Cynthia Levy. Effect of Ethnicity on Liver Transplant for Hepatocellular Carcinoma. Experimental and Clinical Transplantation 2013; 11(4): 339 doi: 10.6002/ect.2013.0008
|
| 88 |
Run-Ze Shang, Shi-Bin Qu, De-Sheng Wang. Reprogramming of glucose metabolism in hepatocellular carcinoma: Progress and prospects. World Journal of Gastroenterology 2016; 22(45): 9933-9943 doi: 10.3748/wjg.v22.i45.9933
|
| 89 |
Bindiya Thakkar, Konstantinos N. Aronis, Maria T. Vamvini, Kelsey Shields, Christos S. Mantzoros. Metformin and Sulfonylureas in Relation to Cancer Risk in Type II Diabetes Patients: A Meta-analysis using primary data of published studies. Metabolism 2013; 62(7): 922 doi: 10.1016/j.metabol.2013.01.014
|
| 90 |
Donna L. White, Fasiha Kanwal, Hashem B. El–Serag. Association Between Nonalcoholic Fatty Liver Disease and Risk for Hepatocellular Cancer, Based on Systematic Review. Clinical Gastroenterology and Hepatology 2012; 10(12): 1342 doi: 10.1016/j.cgh.2012.10.001
|
| 91 |
J K Dyson, Q M Anstee, S McPherson. Non-alcoholic fatty liver disease: a practical approach to treatment. Frontline Gastroenterology 2014; 5(4): 277 doi: 10.1136/flgastro-2013-100404
|
| 92 |
Shih-Wei Lai, Pei-Chun Chen, Kuan-Fu Liao, Chih-Hsin Muo, Cheng-Chieh Lin, Fung-Chang Sung. Risk of Hepatocellular Carcinoma in Diabetic Patients and Risk Reduction Associated With Anti-Diabetic Therapy: A Population-Based Cohort Study. American Journal of Gastroenterology 2012; 107(1): 46 doi: 10.1038/ajg.2011.384
|
| 93 |
Ian F. Godsland. Insulin resistance and hyperinsulinaemia in the development and progression of cancer. Clinical Science 2010; 118(5): 315 doi: 10.1042/CS20090399
|
| 94 |
Diana Soffer, Jiaxiao Shi, Joanie Chung, Joanne E Schottinger, Lauren P Wallner, Rowan T Chlebowski, Scott E Lentz, Reina Haque. Metformin and breast and gynecological cancer risk among women with diabetes. BMJ Open Diabetes Research & Care 2015; 3(1): e000049 doi: 10.1136/bmjdrc-2014-000049
|
| 95 |
Koji Fujita, Hisakazu Iwama, Hisaaki Miyoshi, Joji Tani, Kyoko Oura, Tomoko Tadokoro, Teppei Sakamoto, Takako Nomura, Asahiro Morishita, Hirohito Yoneyama, Tsutomu Masaki. Diabetes mellitus and metformin in hepatocellular carcinoma. World Journal of Gastroenterology 2016; 22(27): 6100-6113 doi: 10.3748/wjg.v22.i27.6100
|
| 96 |
Danielle K. DePeralta, Lan Wei, Sarani Ghoshal, Benjamin Schmidt, Gregory Y. Lauwers, Michael Lanuti, Raymond T. Chung, Kenneth K. Tanabe, Bryan C. Fuchs. Metformin prevents hepatocellular carcinoma development by suppressing hepatic progenitor cell activation in a rat model of cirrhosis. Cancer 2016; 122(8): 1216 doi: 10.1002/cncr.29912
|
| 97 |
Mamatha Bhat, Akiko Yanagiya, Tyson Graber, Nataliya Razumilava, Steve Bronk, Domenick Zammit, Yunhao Zhao, Chadi Zakaria, Peter Metrakos, Michael Pollak, Nahum Sonenberg, Gregory Gores, Maritza Jaramillo, Masahiro Morita, Tommy Alain. Metformin requires 4E-BPs to induce apoptosis and repress translation of Mcl-1 in hepatocellular carcinoma cells. Oncotarget 2017; 8(31): 50542 doi: 10.18632/oncotarget.10671
|
| 98 |
Valter Donadon, Massimiliano Balbi, Maria Dal Mas, Pietro Casarin, Giorgio Zanette. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver International 2010; 30(5): 750 doi: 10.1111/j.1478-3231.2010.02223.x
|
| 99 |
Jacob Alexander, Michael Torbenson, Tsung‐Teh Wu, Matthew M. Yeh. Non‐alcoholic fatty liver disease contributes to hepatocarcinogenesis in non‐cirrhotic liver: A clinical and pathological study. Journal of Gastroenterology and Hepatology 2013; 28(5): 848 doi: 10.1111/jgh.12116
|
| 100 |
Grace Sun, Sangeeta R. Kashyap. Cancer Risk in Type 2 Diabetes Mellitus: Metabolic Links and Therapeutic Considerations. Journal of Nutrition and Metabolism 2011; 2011: 1 doi: 10.1155/2011/708183
|
| 101 |
Takumi Kawaguchi, Eitaro Taniguchi, Yasuyo Morita, Miki Shirachi, Ikuo Tateishi, Eisuke Nagata, Michio Sata. Association of exogenous insulin or sulphonylurea treatment with an increased incidence of hepatoma in patients with hepatitis C virus infection. Liver International 2010; 30(3): 479 doi: 10.1111/j.1478-3231.2009.02191.x
|
| 102 |
Chang-I. Chen, Ching-Feng Kuan, Yu-Ann Fang, Shing-Hwa Liu, Ju-Chi Liu, Li-Li Wu, Chun-Jen Chang, Hsuan-Chia Yang, Jaulang Hwang, James S. Miser, Szu-Yuan Wu. Cancer Risk in HBV Patients With Statin and Metformin Use. Medicine 2015; 94(6): e462 doi: 10.1097/MD.0000000000000462
|
| 103 |
Satoko Umetsu, Hiroki Mizukami, Takeshi Saito, Chiaki Uchida, Akiko Igawa, Kazuhiro Kudo, Chieko Itabashi, Sho Osonoi, Guo Danyang, Takanori Sasaki, Soroku Yagihashi, Kenichi Hakamada. Diabetes, an independent poor prognostic factor of non-B non-C hepatocellular carcinoma, correlates with dihydropyrimidinase-like 3 promoter methylation. Scientific Reports 2020; 10(1) doi: 10.1038/s41598-020-57883-1
|
| 104 |
Chia-Hui LEE, Huang-Meng CHEN, Li-Ke YEH, Meng-Yen HONG, Guewha Steven HUANG. Dosage-dependent Induction of Behavioral Decline in Caenorhabditis elegans by Long-term Treatment of Static Magnetic Fields. Journal of Radiation Research 2012; 53(1): 24 doi: 10.1269/jrr.11057
|
| 105 |
Hui Zhang, Chun Gao, Long Fang, Hong-Chuan Zhao, Shu-Kun Yao. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: a meta-analysis. Scandinavian Journal of Gastroenterology 2013; 48(1): 78 doi: 10.3109/00365521.2012.719926
|
| 106 |
D. Grahame Hardie. AMP-activated protein kinase: a cellular energy sensor with a key role in metabolic disorders and in cancer. Biochemical Society Transactions 2011; 39(1): 1 doi: 10.1042/BST0390001
|
| 107 |
Emily M. Ko, Til Stürmer, Jin-Liern Hong, Wendy Camelo Castillo, Victoria Bae-Jump, Michele Jonsson Funk. Metformin and the risk of endometrial cancer: A population-based cohort study. Gynecologic Oncology 2015; 136(2): 341 doi: 10.1016/j.ygyno.2014.12.001
|
| 108 |
Catherine Mezzacappa, Nadim Mahmud, Marina Serper, Binu V. John, Tamar H. Taddei, David E. Kaplan. HCC is associated with diabetes and longitudinal blood glucose control in a national cohort with cirrhosis. Hepatology Communications 2023; 7(12) doi: 10.1097/HC9.0000000000000344
|
| 109 |
Ram C. Shankaraiah, Elisa Callegari, Paola Guerriero, Alessandro Rimessi, Paolo Pinton, Laura Gramantieri, Enrico M. Silini, Silvia Sabbioni, Massimo Negrini. Metformin prevents liver tumourigenesis by attenuating fibrosis in a transgenic mouse model of hepatocellular carcinoma. Oncogene 2019; 38(45): 7035 doi: 10.1038/s41388-019-0942-z
|
| 110 |
Etsuko Hashimoto, Katsutoshi Tokushige. Hepatocellular carcinoma in non‐alcoholic steatohepatitis: Growing evidence of an epidemic?. Hepatology Research 2012; 42(1): 1 doi: 10.1111/j.1872-034X.2011.00872.x
|
| 111 |
Mohsen Janghorbani, Mohsen Dehghani, Mohammad Salehi-Marzijarani. Systematic Review and Meta-analysis of Insulin Therapy and Risk of Cancer. Hormones and Cancer 2012; 3(4): 137 doi: 10.1007/s12672-012-0112-z
|
| 112 |
Abd Elkhalek Hamed. The association between diabetes and liver disease: The need for a consensus. Arab Journal of Gastroenterology 2014; 15(3-4): 166 doi: 10.1016/j.ajg.2014.09.002
|
| 113 |
Hui Chen, Yi Xin, Yuting Yang, Fei Li, Guoliang Cheng, Xinxin Zhang. Related Factors and Risk Prediction of Type 2 Diabetes Complicated with Liver Cancer. 2019 IEEE International Conference on Mechatronics and Automation (ICMA) 2019; : 2138 doi: 10.1109/ICMA.2019.8816301
|